Although estrogen receptor (ER)– and progesterone receptor (PR)–positive (ER+/PR+) breast cancers are associated with a higher response rate to current therapies, innate and acquired resistance can occur, which represent a significant treatment challenge due to the likelihood of cancer recurrence and dissemination to other organs. This evidence concerns the gene PGR and cancer.